Our Center has published numerous manuscripts in peer-reviewed journals across a range of disciplines, including infectious disease, rheumatology, dermatology, immunology, neuroinflammation, neuropsychology, sex and gender-based medicine, public health, and quality of life research.
- Clarke DJB, Rebman AW, Fan J, Soloski MJ, Aucott JN, Ma’ayan A. Gene set predictor for post-treatment Lyme disease. Cell Rep Med. 2022 Nov 15;3(11):100816. doi: 10.1016/j.xcrm.2022.100816. PMID: 36384094; PMCID: PMC9729821. Distinct gene expression RNA-Seq signatures were identified for acute Lyme disease and post treatment Lyme disease. These mRNA-based signatures can potentially be utilized in a diagnostic biomarker panel to confirm a clinical diagnosis of acute Lyme disease or post treatment Lyme disease. Read entire article
- Marvel CL, Alm KH, Bhattacharya D, Rebman AW, Bakker A, Morgan OP, Creighton JA, Kozero EA, Venkatesan A, Nadkarni PA, Aucott JN. A multimodal neuroimaging study of brain abnormalities and clinical correlates in post treatment Lyme disease. PLoS One. 2022 Oct 26;17(10):e0271425. doi: 10.1371/journal.pone.0271425. PMID: 36288329; PMCID: PMC9604010. Functional abnormalities as well as distinct structural changes in the white brain matter of Lyme disease patients were discovered in this specialized brain imaging study utilizing funcitonal MRI (fMRI) and diffusion tensor imaging (DTI). Read Entire Article
- Kim Y, Rebman AW, Johnson TP, Wang H, Yang T, Colantuoni C, Bhargava P, Levy M, Calabresi PA, Aucott JN, Soloski MJ, Darrah E. Peptidylarginine Deiminase 2 Autoantibodies Are Linked to Less Severe Disease in Multiple Sclerosis and Post-treatment Lyme Disease. Front Neurol. 2022 Jun 6;13:874211. doi: 10.3389/fneur.2022.874211. PMID: 35734473; PMCID: PMC9207393. In this study PADI2 expression was observed in diverse regions and cells of the central nervous system, and anti-PAD2 autoantibodies were associated with less severe symptoms in subsets of patients with multiple sclerosis and post treatment Lyme disease. These data suggest that anti-PAD2 antibodies may reduce inflammation in diseases which are united by high PADI2 expression in the target tissue. The implications of these results are that anti-PAD2 antibodies may hold potential as a novel prognostic biomarker to define less severe subsets in MS and PTLD and help inform future development of mechanism-guided therapies that target PAD2 in these diseases. Read Entire Article
- Servellita V, Bouquet J, Rebman A, Yang T, Samayoa, E, Miller S, Stone M, Lanteri M, Busch M, Tang P, Morshed M, Soloski M, Aucott JN, Chiu CY. A diagnostic classifier for gene expression-based identification of early Lyme disease. Commun Med 2, 92. July 22, 2022. This study showed that a new gene expression Lyme disease classifier (LDC) blood test could diagnose early Lyme disease. The LDC could identify early Lyme disease patients (those presenting with symptoms within weeks of a tick bite) accurately, even before standard laboratory tests turn positive. In the future, the LDC may be clinically useful as a test for Lyme disease to diagnose patients earlier in the course of their illness thus guiding more timely and effective treatment for the infection. Read Entire Article
- Motamed M, Liblik K, Miranda-Arboleda AF, Wamboldt R, Wang CN, Cingolani O, Rebman AW, Novak CB, Aucott JN, Farina JM, Baranchuk A. Disseminated Lyme disease and dilated cardiomyopathy: A systematic review. Trends Cardiovasc Med. 2022 Jun 3:S1050-1738(22)00077-9. doi: 10.1016/j.tcm.2022.05.010. Epub ahead of print. PMID: 35667636. This study is a systematic review summarizing existing literature on the association between late disseminated Lyme disease and dilated cardiomyopathy (DCM). Although most studies identified evidence associating Borrelia-infection with DCM, further research is required to isolate late disseminated Borrelia infection as a causative agent of DCM. Read Entire Article
- Berkenstock MK, Long K, Miller JB, Burkholder BB, Aucott JN, Jabs DA. Scleritis in Lyme Disease. Am J Ophthalmol. 2022 Sep;241:139-144. doi: 10.1016/j.ajo.2022.04.017. Epub 2022 May 2. PMID: 35513033. The study shows that Lyme disease can be an uncommon cause of scleritis in endemic areas. Read Entire Article
- Miller JB, Albayda J, Aucott JN. The Value of Musculoskeletal Ultrasound for Evaluation of Postinfectious Lyme Arthritis. J Clin Rheumatol. 2022 Mar 1;28(2):e605-e608. doi: 10.1097/RHU.0000000000001732. PMID: 33790205. Marked inflammatory change can be seen using ultrasound in selected patients with Lyme arthritis. Systematic sonographic evaluation is needed to further evaluate pathology and treatment response. Read Abstract
- Aucott JN, Yang T, Yoon I, Powell D, Geller SA, Rebman AW. Risk of post-treatment Lyme disease in patients with ideally-treated early Lyme disease: A prospective cohort study. Int J Infect Dis. 2022 Mar;116:230-237. doi: 10.1016/j.ijid.2022.01.033. Epub 2022 Jan 21. PMID: 35066160. This is the largest peer-reviewed prospective controlled study in the US that specifically focuses on the longer-term outcomes of early diagnosed and promptly treated Lyme disease patients. Results found that functionally impairing persistent symptoms occurred in 14% of the early treated Lyme disease patients compared with 4% in the healthy control group. Results confirm that Lyme disease can trigger persistent symptoms, such as severe fatigue, body pain and cognitive challenges, despite early treatment with standard of care antibiotics. Read Entire Article
- Curriero FC, Wychgram C, Rebman AW, Corrigan AE, Kvit A, Shields T, Aucott JN. The Lyme and Tickborne Disease Dashboard: A map-based resource to promote public health awareness and research collaboration. PLoS One. 2021 Dec 1;16(12):e0260122. doi: 10.1371/journal.pone.0260122. PMID: 34851988; PMCID: PMC8635336. The Johns Hopkins Lyme and Tickborne Disease Dashboard, is a new tool that harnesses the power of geography to help track and raise awareness of tick borne illness. The dashboard is unique in applying a geographic lens to tick borne diseases, aiming not only to become a global tracker but also to help fuel research and scientific collaboration. Read Entire Article
- Bobe JR, Jutras BL, Horn EJ, Embers ME, Bailey A, Moritz RL, Zhang Y, Soloski MJ, Ostfeld RS, Marconi RT, Aucott J, Ma’ayan A, Keesing F, Lewis K, Ben Mamoun C, Rebman AW, McClune ME, Breitschwerdt EB, Reddy PJ, Maggi R, Yang F, Nemser B, Ozcan A, Garner O, Di Carlo D, Ballard Z, Joung HA, Garcia-Romeu A, Griffiths RR, Baumgarth N, Fallon BA. Recent Progress in Lyme Disease and Remaining Challenges Front Med (Lausanne). 2021 Aug 18;8:666554. doi: 10.3389/fmed.2021.666554. PMID: 34485323; PMCID: PMC8416313. This study summarizes progress and remaining challenges in Lyme disease and underscores the need for significantly more research funding to address outstanding questions regarding the diagnosis, clinical presentation, treatments, and underlying molecular mechanisms that trigger persistent disease. Read Entire Article
- Heaney CD, Moon KA, Ostfeld RS, Pollak J, Poulsen MN, Hirsch AG, DeWalle J, Aucott JN, Schwartz BS. Relations of peri-residential temperature and humidity in tick-life-cycle-relevant time periods with human Lyme disease risk in Pennsylvania, USA. Sci Total Environ. 2021 Nov 15;795:148697. doi: 10.1016/j.scitotenv.2021.148697. Epub 2021 Jul 1. PMID: 34252768. This study shows how changing temperature and humidity could increase or decrease human Lyme disease risk. Read Abstract
- Goff ZD, Zaeh SE, Poku MK, Aucott JN, Gelber AC. Evolving distal signs. Cleve Clin J Med. 2021 Jun 2;88(6):310-312. doi: 10.3949/ccjm.88a.20126. PMID: 34078613. This case study is an example of an unusual way infectious endocarditis can present following a history of tick bites and infection with Borrelia burgdorferi and Ehrlichia. Read Entire Article
- Aucott JN, Rebman AW. Long-haul COVID: heed the lessons from other infection-triggered illnesses. Lancet. 2021 Mar 13;397(10278):967-968. doi: 10.1016/S0140-6736(21)00446-3. Epub 2021 Mar 5. PMID: 33684352; PMCID: PMC7952095. There are important lessons to learn and pitfalls to avoid from Lyme disease clinical care and research (and other infection triggered conditions such as myalgic encephalitis/chronic fatigue syndrome and fibromyalgia) that are relevant to Longhaul COVID. Read Published Letter to Lancet
- Clarke DJB, Rebman AW, Bailey A, Wojciechowicz ML, Jenkins SL, Evangelista JE, Danieletto M, Fan J, Eshoo MW, Mosel MR, Robinson W, Ramadoss N, Bobe J, Soloski MJ, Aucott JN and Ma’ayan A. Predicting Lyme Disease From Patients’ Peripheral Blood Mononuclear Cells Profiled With RNA-Sequencing. Front. Immunol. 12:636289. doi: 10.3389/fimmu.2021.636289 Using machine learning classifiers, the study shows that Lyme patients can be distinguished from healthy controls as well as from COVID-19 patients. Read Entire Article
- Rebman AW, Yang T, Aucott JN, Mihm EA, West SK. Contrast Sensitivity Loss in Patients With Posttreatment Lyme Disease. Trans. Vis. Sci. Tech. 2021;10(3):27. doi:https://doi.org/10.1167/tvst. 10.3.27. This study found that visual contrast sensitivity (CS) impairment in patients with post treatment Lyme disease (PTLD) is linked to signs of cognitive and neurologic impairment and may be a marker of illness severity. Read Entire Article
- Novak CB, Scheeler VM, Aucott JN. Lyme Disease in the Era of CoVID-19: A Delayed Diagnosis and Risk for Complications. Case Reports in Infectious Diseases, vol. 2021, Article ID 6699536, 4 pages, 2021. https://doi.org/10.1155/2021/6699536. This report presents a Lyme disease case that was initially misdiagnosed in the spring of 2020 resulting in disseminated infection and sixth nerve palsy and highlights new challenges facing healthcare delivery in the era of COVID-19. The objective of this report is to describe the obstacles for diagnosticians during the pandemic and also to discuss the potential beneficial application of telemedicine in the early diagnosis of Lyme disease during the COVID-19 era as well as in the future. Read Entire Article
- Rebman AW, Yang T, Mihm EA, et al. The presenting characteristics of erythema migrans vary by age, sex, duration, and body location. Infection 49, 685–692 (2021). https://doi.org/10.1007/s15010-021-01590-0. The erythema migrans (EM) rash, when present, is often the first clinical sign of Lyme disease. This study shows that EM presentations vary with age, sex, EM duration, body location, and timing of initiation of antibiotics. Understanding this EM variability can help physicians and the general public better recognize the rash and improve early diagnosis and treatment. Read Abstract
- Rebman AW, Yang T, Aucott JN. Symptom heterogeneity and patient subgroup classification among US patients with posttreatment Lyme disease: an observational study. BMJ Open 2021;11:e040399. doi: 10.1136/bmjopen-2020-040399. This study showed that clinicially relevant patient subgroups can be identified in the heterogeneous symptoms reported in well-defined post treatment Lyme disease. Read Entire Article
- Mosel MR, Rebman AW, Carolan HE, Montenegro T, Lovari R, Schutzer SE, Ecker DJ, Yang T, Ramadoss NS, Robinson WH, Soloski MJ, Eshoo MW, Aucott JN. Molecular Microbiological and Immune Characterization of a Cohort of Patients Diagnosed with Early Lyme Disease. J Clin Microbiol. 2020 Dec 17;59(1):e00615-20. doi: 10.1128/JCM.00615-20. PMID: 33087434; PMCID: PMC7771464. This study showed Lyme disease patient subgroups can be identified using amplified PCR-based direct detection approaches. Read Entire Article
- Hirsch AG, Poulsen MN, Nordberg C, Moon KA, Rebman AW, Aucott JN, Heaney CD and Schwartz BS Risk factors and Outcomes of Treatment Delays in Lyme Disease: A Population-Based Retrospective Cohort Study. 26 November 2020 Frontiers in Medicine 7:560018. doi: 10.3389/fmed.2020.560018. This study shows that treatment delays increase the risk of persistent illness in Lyme disease and indicate that improved Lyme disease diagnosis and prevention strategies are needed. Read Entire Article
- Fitzgerald BL, Graham B, Delorey MJ, Pegalajar-Jurado A, Islam MN, Wormser GP, Aucott JN, Rebman AW, Soloski MJ, Belisle JT, Molins CR. Metabolic Response in Patients With Post-treatment Lyme Disease Symptoms/Syndrome. Clin Infect Dis. 2021 Oct 5;73(7):e2342-e2349. doi: 10.1093/cid/ciaa1455. PMID: 32975577; PMCID: PMC8492154. This study reveals that objective metabolite-based measurements differ between Lyme disease patients that develop persistent symptoms following antibiotic treatment (PTLD) and those that are clinically cured. These differences could be useful in better identifying, differentiating, and understanding the underlying biochemistry of patients with persistent symptoms in Lyme disease. Read Abstract
- Gutierrez-Hoffmann MG, O’Meally RN, Cole RN, Tiniakou E, Darrah E and Soloski MJ Borrelia burgdorferi-Induced Changes in the Class II Self-Immunopeptidome Displayed on HLA-DR Molecules Expressed by Dendritic Cells. (2020) Front. Med. 7:568. doi: 10.3389/fmed.2020.00568. This study finds that Lyme disease bacteria induce changes in self-immunopeptides expressed by dendritic cells. Lyme disease infection and genetic susceptibility to autoimmune diseases may trigger breakdown in tolerance to self-antigens & contribute to dysregulated immunity, autoimmune illness, & persistent symptoms. Read Entire Article
- Morrissette M, Pitt N, González A, Strandwitz P, Caboni M, Rebman AW, Knight R, D’Onofrio A, Aucott JN, Soloski MJ, Lewis K. A Distinct Microbiome Signature in Post Treatement Lyme Disease Patients. American Society for Microbiology. September 2020. DOI: 10.1128/mBio.02310-20 This study found a distinct post treatment Lyme disease microbiome signature that could present a potential new objective Lyme diagnostic tool and novel avenue for Lyme disease therapeutics. Read Entire Article
- Burlina PM, Joshi, NJ, Mathew PA, Paul W, Rebman AW, Aucott JN. AI-based detection of erythema migrans and disambiguation against other skin lesions. Computers in Biology and Medicine. October 2020. doi:10.1016/j.compbiomed.2020.103977. This study shows an artificial intelligence and deep learning-based approach can improve the early detection of the Lyme disease rash. Read Entire Article
- Rebman AR and Aucott JN. Post-Treatment Lyme Disease as a Research Model for Persistent Symptoms in Lyme Disease. Frontiers of Medicine (February 25 2020) 7:57.doi:10.3389/fmed.2020.00057. This paper reviews the current literature on the diagnosis, etiology, risk factors, treatments and heterogeneity of patients with persistent symptoms of Lyme disease. The meaning and relevance of existing patient subgroups are discussed, as are future research priorities, including the need to develop illness biomarkers, elucidate the biologic mechanisms of disease, drive improvements in therapeutic options, and study additional subgroups. Read Entire Article
- Dennison R, Novak C, Rebman A,, Venkatesan A, Aucott JN. Case Study: Lyme Disease with Erythema Migrans and Seventh Nerve Palsy in an African-American Man. December 30, 2019 Cureus 11(12): e6509. doi:10.7759/cureus.6509. Few studies have sought to investigate whether racial or other demographic factors influence patient care or outcomes in Lyme disease. This study aims to improve provider awareness of Lyme disease risk factors and racial differences in diagnostic findings such as the skin rash and could help improve early diagnosis and reduce risk of persistent symptoms. Read Entire Article
- Fallon BA, Zubcevik N, Bennett C, Doshi S, Rebman AW, Kishon R, Moeller JR, Octavien NR and Aucott JN. The General Symptom Questionnaire-30 (GSQ-30): A Brief Measure of Multi-System Symptom Burden in Lyme Disease. Frontiers in Medicine. 6:283. doi: 10.3389/fmed.2019.00283 December 2019. This study shows that the General Symptom Questionnaire-30 (GSQ-30) is a valid and reliable self-report instrument that clinicians and researchers could use to assess the multi-system symptom burden and response to treatment among patients with acute and post-treatment Lyme disease. The GSQ-30 may prove valuable in future precision medicine studies as a quantitative clinical measure for assessing the clinical relevance of biomarkers and effectiveness of treatments. Read Entire Article.
- Zhou Y, Qin S, Sun M, Tang L, Yan X, Kim TE, Caballero J, Glusman G, Brunkow ME, Soloski MJ, Rebman AW, Scavarda C, Cooper D, Omenn GS, Moritz RL, Wormser GP, Price ND, Aucott JN, Hood L. Measurement of Organ-Specific and Acute-Phase Blood Protein Levels in Early Lyme Disease. Journal of Proteome Research 2020 19 (1), 346-359 DOI: 10.1021/acs.jproteome.9b00569. October 2019. This study analyzed serum proteins of Lyme disease patients relative to healthy controls to identify specific proteins that may serve as candidate blood biomarkers for a more reliable diagnostic test to detect Borrelia burgdorferi infection at the earliest stage possible. Read Abstract
- Mosel MR, Carolan HE, Rebman AW, Castro S, Massire C, Ecker DJ, Soloski MJ, Aucott JN, Eshoo MW. Molecular Testing of Serial Blood Specimens from Patients with Early Lyme Disease during Treatment Reveals Changing Coinfection with Mixtures of Borrelia burgdorferi Genotypes. Antimicrobial Agents and Chemotherapy. June 2019. 63 (7) e00237-19. This pilot study showed a direct molecular Lyme disease diagnostic test could be used to identify and genotype Borrelia burgdorferi during antibiotic treatment in early Lyme disease patients. Findings suggest that the host immune system or differential antibiotic susceptibility might have played a role in observed genotypic shift. Read Abstract
- Burlina PM, Joshi NJ, Ng E, Billings SD, Rebman AW, Aucott JN. Automated Detection of Erythema Migrans and Other Confounding Skin Lesions via Deep Learning. Computers in Biology and Medicine. Volume 105, Pages 151-156. February 2019. This study shows that deep machine learning can be utilized to more accurately identify erythema migrans rashes in early Lyme disease from patient photos. Read Entire Article.
- Coughlin JM†, Yang T†, Rebman AW, Bechtold, KT, Du Y, Mathews WB, Lesniak WG, Mihm EA, Frey SM, Marshall ES, Rosenthal HB, Reekie, TA, Kassiou M, Dannals, RF, Soloski MJ†, Aucott JN†, Pomper MG†. PET Imaging of Glial Activation in Patients with Post Treatment Lyme Disease Symptoms: a pilot study using [11C]DPA-713 PET. Journal of Neuroinflammation. December 2018. 15:346. †Contributed equally. This study uses PET imaging to quantify glial activation and results show patients with Post Treatment Lyme Disease have elevated central nervous system immune activation as compared to controls. Read Entire Article.
- Blum LK, Adamska JZ, Martin DS, Rebman AW, Elliott SE, Cao RRL, Embers ME, Aucott JN, Soloski MJ, Robinson WH. Robust B Cell Reponses Predict Rapid Resolution of Lyme Disease. Frontiers of Immunology. July 2018. 9:1634. This study shows that robust B cell plasmablasts predict more rapid resolution of Lyme disease whereas poor plasmablast reponses are associated with a longer duration of symptoms. Read Entire Article.
- Rebman AW, Wang L, Yang T, Marsteller JA, Murphy SME, Uriyo M, Mihn EA, Weinstein ER, Fagan P, Aucott JN. Incidence of Lyme Disease Diagnosis in a Maryland Medicaid Population. American Journal of Epidemiology, Volume 187, Issue 10, Pages 2201-2209, October 2018. This represents the first examination of the epidemiology of Lyme disease using the analysis of health insurance claims data from publicly insured individuals. Read Abstract.
- Touradji P, Aucott JN, Yang T, Rebman AW, Bechtold KT. Cognitive Decline in Post-Treatment Lyme Disease Syndrome. Archives of Clinical Neuropsychology. June 2018. acy051. This study found objective evidence of decline in cognitive functioning in some PTLDS participants, with particular measurable cognitive decline in verbal memory and processing speed. Read Abstract.
- Hirsch AG, Herman RJ, Rebman AW, Moon KA, Aucott JN, Heaney C, Schwartz BS. Obstacles to diagnosis and treatment of Lyme disease in the USA. BMJ Open. 2018. 8:3021367 This study explores factors which may contribute to a delay in diagnosis and treatment of Lyme disease. Read Entire Article.
- Weinstein ER, Rebman AW, Aucott JN, Johnson-Greene D, Bechtold KT. Sleep Quality in Well-defined Lyme Disease: A Clinical Cohort Study in Maryland. Sleep. Volume 41, Issue 5, May 2018, zsy035. This study found poor sleep quality associated with pain among both patients with early Lyme disease and those who develop Post-Treatment Lyme Disease Syndrome. Read Abstract.
- Rebman AW, Bechtold KT, Yang T, Mihm EA, Soloski MJ, Novak CB and Aucott JN. The Clinical, Symptom, and Quality-of-Life Characterization of a Well-Defined Group of Patients with Post Treatment Lyme Disease Syndrome. Frontiers in Medicine.4:224. December 14, 2017. The study demonstrates that patients with well-documented post-treatment Lyme disease syndrome are highly symptomatic, with statistically and clinically significant impacts on quality of life compared to non-Lyme infected healthy controls. Read Entire Article.
- Cheryl Novak, Andrew Harrison and John Aucott. Early Disseminated Lyme Disease with Carditis Complicated by Post Treatment Lyme Disease Syndrome. Case Reports in Infectious Diseases. Article ID 5847156. October 31, 2017. This case study presents the severity of illness that can result from delayed diagnosis and misdiagnosis of Lyme disease, including Lyme carditis and post-treatment Lyme disease syndrome. Read Entire Article.
- Kathleen T Bechtold, Alison W. Rebman, Lauren A. Crowder, Doug Johnson-Greene, John N. Aucott. Standardized Symptom Measurement of Individuals with Early Lyme Disease Over Time. Archives of Clinical Neuropsychology 2017 32(2);129-141. In this longitudinal analysis, ideally treated patients with early Lyme disease recovered well overall however a small subgroup continued to suffer with symptom that lead to functional decline. Read Entire Article.
- John N. Aucott, Mark J. Soloski, Alison W. Rebman, Lauren A. Crowder, Lauren J. Lahey, Catriona A. Wagner, William H. Robinson, Kathleen T. Bechtold. CCL19 as a Chemokine Risk Factor for Post-Treatment Lyme Disease Syndrome: A Prospective Clinical Cohort Study. Clinical and Vaccine Immunology 2016 23(9): 757-66. This study suggests the relevance of the T-cell chemokine CCL19 during both acute infection with Lyme disease and as an immunologic risk factor for PTLDS during the post-treatment phase. Read Entire Article.
- Jerome Bouquet, Mark J. Soloski, Andrea Swei, Chris Cheadle, Scot Federman, Jean-Noel Billaud, Alison W. Rebman, Beniwende Kabre, Richard Halpert, Meher Boorgula, John N. Aucott, Charles Y. Chiu. Longitudinal Transcriptome Analysis Reveals a Sustained Differential Gene Expression Signature in Patients Treated for Acute Lyme Disease. mBio 2016 7(1). This study found a differential gene expression signature in patients with early Lyme disease that persisted to some degree for up to six months following completion of antibiotic therapy. Read Entire Article.
- Lauren J. Lahey, Michael W. Panas, Rong Mao, Michelle Delanoy, John J. Flanagan, Steven R. Binder, Alison W. Rebman, Jose G. Montoya, Mark J. Soloski, Allen C. Steere, Raymond J. Dattwyler, Paul M. Arnaboldi, John N. Aucott, William H. Robinson. Development of a Multiantigen Panel for Improved Detection of Borrelia burgdorferi Infection in Early Lyme Disease. Journal of Clinical Microbiology. Volume 53, Issue 12, December 2015. The article shows that a newly developed 10-antigen panel can improve sensitivity of blood testing in early Lyme disease. http://www.ncbi.nlm.nih.gov/pubmed/26447113
- Alison W. Rebman, John N. Aucott, Eric R. Weinstein, Kathleen T. Bechtold, Katherine C. Smith, Lori Leonard. Living in Limbo: Contested Narratives of Patients with Chronic Symptoms Following Lyme Disease. Qualitative Health Research. December 1, 2015. Similar to other contested or medically unexplained syndromes, semi-structured interviews suggest that the social sequelae of PTLDS/CLD can be equally protracted as the physical effects of this illness. http://www.ncbi.nlm.nih.gov/pubmed/26631681
- Crystal S. F. Cheung, Kyle W. Anderson, Kenia Y. Villatoro Benitez, Mark J. Soloski, John N. Aucott, Karen W. Phinney, Illarion V. Turko. Quantification of Borrelia burgdorferi Membrane Proteins in Human Serum: A New Concept for Detection of Bacterial Infection. Analytical Chemistry. Volume 87, Number 22, November 2015. This collaborative proof of concept report shows that a new method can accurately identify a major B. burgdorferi lipoprotein in a small sample of patients with early Lyme disease. http://www.ncbi.nlm.nih.gov/pubmed/26491962
- John N Aucott. Posttreatment Lyme disease syndrome. Infectious Disease Clinics of North America 2015 29(2);309-23. This review article offers an overview of current research into diagnosis, treatment, and proposed mechanisms for post-treatment Lyme disease syndrome. Read Abstract.
- Emily R. Adrion, John N. Aucott, Klaus W. Lemke, Jonathan P. Weiner. Health Care Costs, Utilization and Patterns of Care following Lyme Disease. PLoS ONE. Volume 10, Issue 2. February 4, 2015. Healthcare claims study shows Lyme disease costs upward of $1.3 billion to treat. Read entire article
- Lauren A. Crowder, Victoria A. Yedlin, Eric R. Weinstein, John N. Aucott, Kathleen B. Kortte. Lyme disease and post-treatment Lyme disease syndrome: the neglected disease in our own backyard. Public Health. Volume 128, Issue 9. September 9, 2014. The need for further understanding and communication presents an opportunity for public health research and education in Lyme disease and the sequelae of PTLDS. Read abstract
- Alison W. Rebman, Lauren A. Crowder, Allison Kirkpatrick, John N. Aucott. Characteristics of seroconversion and implications for diagnosis of post-treatment Lyme disease syndrome: acute and convalescent serology among a prospective cohort of early Lyme disease patients. Clinical Rheumatology. June 13, 2014. The lack of seroconversion in a subset of patients, highlights the limitations of using serology alone in identifying early Lyme disease. Read abstract
- Mark J. Soloski, Lauren A. Crowder, Lauren J. Lahey, Catriona A. Wagner, William H. Robinson, and John N. Aucott. Serum Inflammatory Mediators as Markers of Human Lyme Disease Activity. PLOS ONE. (2014) The levels of serum chemokines and the levels of expression of their respective chemokine receptors on T cell subsets may prove to be informative biomarkers for Lyme disease and related to specific disease manifestations. Read abstract.
- John N. Aucott, Lauren A.Crowder, and Kathleen B. Kortte. Development of a foundation for a case definition of post-treatment Lyme disease syndrome. International Journal of Infectious Diseases 17 (2013) This article describes the initial findings of the SLICE Study, showing results from the first prospective controlled study in the United States designed to specifically measure symptom and health related quality of life outcomes after the antibiotic treatment of early Lyme disease. Read abstract.
- Schutzer SE, Berger BW, Krueger JG, Eshoo MW, Ecker DJ, Aucott JN.. Atypical Erythema Migrans in Patients with PCR-Positive Lyme Disease. Emerging Infectious Diseases. 2013;19(5):815-817. doi:10.3201/eid1905.120796. This report re-emphasizes that the majority of proven cases of erythema migrans do not have the text book “bull’s eye” appearance and therefore may be harder for patients and physicians to recognize as a sign of early Lyme disease. Read entire article.
- Eshoo MW, Crowder CC, Rebman AW, Rounds MA, Matthews HE, Picuri JM, Soloski MJ, Ecker DJ, Schutzer SE, Aucott JN. Direct molecular detection and genotyping of Borrelia burgdorferi from whole blood of patients with early Lyme disease. PLoS One. 2012;7(5):e36825. doi: 10.1371/journal.pone.0036825. Epub 2012 May 8. PMID: 22590620; PMCID: PMC3348129. This research collaboration shows that new state of the art methods can accurately detect the minute amount of DNA of the bacteria Borrelia burgdorferi in the blood stream of patients with early untreated Lyme disease. Read abstract.
- Aucott JN, Crowder LA, Yedlin V, Kortte KB. Bull’s-Eye and Nontarget Skin Lesions of Lyme Disease: An Internet Survey of Identification of Erythema Migrans. Dermatol Res Pract. 2012;2012:451727. doi: 10.1155/2012/451727. Epub 2012 Oct 24. PMID: 23133445; PMCID: PMC3485866. The results of this survey demonstrate that individuals are unfamiliar with the atypical skin manifestations of early Lyme disease. Read abstract.
- John N. Aucott, Ari Seifter, and Alison W Rebman. Probable late lyme disease: a variant manifestation of untreated Borrelia burgdorferi infection. BMC Infectious Diseases 2012, 12:173. This review of patients seen in the community practice of medicine shows that some patients with untreated late Lyme disease may have only chronic symptoms and do not have the classic objective findings of Lyme arthritis or nerve damage. Read entire article.
- John N. Aucott, Alison W. Rebman, Lauren A. Crowder, & Kathleen B. Kortte. Post-treatment Lyme Disease syndrome symptomatology and the impact on life functioning: is there something here?Quality of Life Research. Published online: February 1, 2012. This study aims to describe a cohort of participants with early, untreated Lyme disease, and characterize post-antibiotic treatment symptoms and functional impact of post-treatment Lyme disease syndrome over time. Read abstract.
- John N. Aucott, Ari Seifter. Misdiagnosis of early Lyme disease as the summer flu. Orthopedic Reviews 2011 3:2. This case report provides an example of how Lyme disease can present with viral-like symptoms that may remain unrecognized. Read Entire Article.
- Alison Schwarzwalder, MPH; Michael F. Schneider, MS; Alison Lydecker, MPH; and John N. Aucott, MD. Sex Differences in the Clinical and Serologic Presentation of Early Lyme Disease: Results From a Retrospective Review. Gender Medicine. Volume 7, Issue 4, 2010. This paper shows for the first time that women’s antibody responses used to diagnose Lyme disease may not be equivalent to those seen in men. Read abstract
- Ari Seifter, Alison Schwarzwalder, Kate Geis, John Aucott. The Utility of “Google Trends for Epidemiological Research: Lyme Disease as an Example. Geospatial Health 4(2), 2010, pp. 135-137. Article examines the potential of the Internet for monitoring epidemics of disease such as Lyme. Read abstract.
- Ari Seifter, and John N. Aucott, MD. Unusual Presentation of Lyme Disease: Horner Syndrome with Negative Serology Candis Morrison, PhD, CRNP, J Am Board Fam Med 2009;22:219 –222. This article highlights an unusual presentation that most physicians would not consider to be a result of Lyme disease. Read entire article.
- John Aucott, Candis Morrison, Beatriz Munoz, Peter C Rowe, Alison Schwarzwalder and Sheila K West. Diagnostic Challenges of Early Lyme Disease: Lessons from a Community Case Series. BMC Infectious Diseases 2009, 9:79 Accepted: 1 June 2009. This manuscript describes the variability in the presenting symptoms of Lyme disease and difficulty with its diagnosis in the community-based practice of medicine. It shows physicians’ current, widespread difficulty in making accurate diagnosis and treatment decisions in early Lyme. Read entire article
Abstracts Presented at National Meetings about the Slice Study
- Temporal patterns of early cytokine immune response to infection with B burgdorferi. Aucott J, Schwarzwalder A, Miagkov A, Soloski M. Presented at the American Society for Tropical Medicine and Hygiene meetings, November 19-22, 2009. Read abstract
- Post-Lyme syndrome, an emerging complication of acute infection with Borrelia burgdorferi. Schwarzwalder A, Johnson-Greene D, Aucott J. Presented at the International Conference on Emerging Infectious Diseases, July 11-15, 2010. See chart
- Another Difference between Boys and Girls: Sex-Based Differences in Lyme Disease. L. A. Crowder, V. A. Yedlin, M. Soloski, J. N. Aucott See chart
- T-cell Immunophenotyping in Early Lyme Disease. L. A. Crowder, J. N. Aucott, M. Soloski See chart
Note: These abstracts describe the SLICE Study, a five-year prospective cohort study conducted through Johns Hopkins Green Spring/Johns Hopkins Bayview examining symptom prevalence, risk factors, natural history, and biomarkers associated with the development of persistent symptoms following exposure to Lyme disease.
